Plandai Biotechnology Inc (OTCMKTS:PLPL) reported that it has extended the deal with USN Worldwide so as to include the European Union. As a result, it will expand Phytofare® complex sales to USN and its manufacturers to the EU. USN spokesperson, Irma Botes, said that the customers’ expectations have increased from their nutrition supplement associates, and they have always remained committed to deliver the superior quality products in the global marketplace.
In last trading session, the stock price of Plandai gained more than 7% to close the trading session at $0.150. The gains came at a share volume of 33,300 compared to average monthly share volume of 75,942. With this, the stock managed to break the narrow range that it was stuck into from last few trading sessions.
Herborium Group, Inc. (OTCMKTS:HBRM) jumped more than 100% to close the trading session at $0.00020 on Tuesday. The gains came at a share volume of 16.16 million compared to monthly average share volume of 3.99 million.
Back in July, the company announced the launch of the next-gen, US and global markets targeted websites for its innovative lead product for natural treatment of rosacrea, AcnEase and acne. The websites and its Mobile versions are an integral part of a deployment of a Digital Marketing Plan introduced in June 2015. The initial weeks of operation recorded 10% increase in sale and 38% jump in traffic. Herborium expects its upcoming quarter to be eleventh successive sales growth quarter compared to same period of 2014.
Fluoropharma Medical Inc (OTCMKTS:FPMI) was one of the OTC stocks in biotech groups that recorded a weak session on Tuesday. The stock declined more than 10% to close the trading session at $0.241 on share volume of 14,400. The company has been advancing improved Diagnostic Tool for the assessment of different forms of coronary artery disease.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: